Patents by Inventor Patrick J. Sinko
Patrick J. Sinko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9999596Abstract: Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.Type: GrantFiled: March 12, 2015Date of Patent: June 19, 2018Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Stanley Stein, Anita Lalloo
-
Patent number: 9763968Abstract: Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.Type: GrantFiled: May 31, 2016Date of Patent: September 19, 2017Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Manjeet Deshmukh, Siva N. Priya Anumolu, Anupa R. Menjoge, Marion K. Gordon
-
Publication number: 20170136087Abstract: A multifunctional polyethylene glycol-based hydrogel that includes a multi-arm polyethylene glycol cross-linking unit covalently bound to at least four multi-arm polyethylene glycol nanocarrier units, wherein each nanocarrier unit includes an agent coupled to the nanocarrier unit and each agent is selected from pH-lowering agents, bioadhesion agents, microbicidal-spermicidal agents, and agents that inhibit free and cell-associated HIV binding, provided that each nanocarrier unit comprises a different agent.Type: ApplicationFiled: November 18, 2016Publication date: May 18, 2017Inventors: Patrick J. Sinko, Michael L. Chikindas, Stanley Stein, Yashveer Singh, Sujata Sundara Rajan, Dayuan Gao, Katia Noll
-
Publication number: 20170042818Abstract: The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.Type: ApplicationFiled: August 22, 2016Publication date: February 16, 2017Applicants: The Trustees of Princeton University, Rutgers, The State University of New JerseyInventors: Robert K. PRUD'HOMME, Patrick J. SINKO, Howard A. STONE, Nathalie M. PINKERTON, Lei SHI, Jiandi WAN, Sherif IBRAHIM, Dayuan GAO
-
Patent number: 9566349Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: GrantFiled: January 8, 2015Date of Patent: February 14, 2017Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Patent number: 9517201Abstract: Novel classes of multi-arm polyalkylene oxide-based materials including PEG nanocarriers, nanogel particles, and aggregated nanogel particles are disclosed. These classes of compositions may be associated with therapeutic agents and targeting moieties, or visibility enhancing agents, and may have a modified surface structure. In some embodiments the PEG-based materials can be made to provide relatively high drug loads with improved solubility and targeted delivery.Type: GrantFiled: April 6, 2009Date of Patent: December 13, 2016Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Stanley Stein, Hilliard Kutscher, Manjeet Deshmukh, Anupa Menjoge, Yashveer Singh, Simi Gunaseelan
-
Patent number: 9457099Abstract: The instant invention relates to polyethylene glycol-based dendrons, otherwise known as PEGtide dendrons, compositions thereof and methods of use.Type: GrantFiled: November 14, 2011Date of Patent: October 4, 2016Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Jieming Gao, Yashveer Singh, Xiaoping Zhang, Matthew S. Palombo, Stanley Stein
-
Publication number: 20160271151Abstract: Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.Type: ApplicationFiled: May 31, 2016Publication date: September 22, 2016Inventors: Patrick J. Sinko, Manjeet Deshmukh, Sivanaga S. Anumolu, Anupa R. Menjoge, Marion Gordon
-
Patent number: 9421194Abstract: The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases.Type: GrantFiled: April 5, 2011Date of Patent: August 23, 2016Assignees: Rutgers, The State University of New Jersey, The Trustees of Princeton UniversityInventors: Robert K. Prud'homme, Patrick J. Sinko, Howard A. Stone, Nathalie M. Pinkerton, Lei Shi, Jiandi Wan, Sherif Ibrahim, Dayuan Gao
-
Patent number: 9421272Abstract: This invention provides multimeric nanocarrier for in vivo delivery of a bioactive agent, comprising at least two peptide monomers reversibly or irreversibly linked with one or more of said bioactive agents, wherein said two or more of said peptide monomers are covalently linked by a biodegradable difunctional moiety, as well as methods of using this nanocarrier.Type: GrantFiled: March 16, 2010Date of Patent: August 23, 2016Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Stanley Stein, Simi Gunaseelan, Shahriar Pooyan, Matthew Sean Palombo, Xiaoping Zhang
-
Publication number: 20160199534Abstract: Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed.Type: ApplicationFiled: December 14, 2015Publication date: July 14, 2016Inventors: Patrick J. Sinko, Stanley Stein, Anupa R. Menjoge, Simi Gunaseelan, Siva Naga Sree Priya Anumolu, Raghavandra Navath
-
Patent number: 9345662Abstract: This invention concerns an in situ biodegradable hydrogel drug delivery system in which the components are assembled in a manner that provides a mechanism for the timed cleavage of a particular amide bond in a covalently linked active agent or of the hydrogel structure.Type: GrantFiled: November 20, 2009Date of Patent: May 24, 2016Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Manjeet Deshmukh, Yashveer Singh, Simi Gunaseelan
-
Patent number: 9211358Abstract: Described is a spray-on hydrogel comprising water-soluble PEG polymers that cross-link in situ to form a hydrogel such that the cross-links are reversible. The hydrogel can be useful as a drug delivery composition, wound dressing or surgery adjuvant. Polyethylene glycol polymer and cross-linker solutions are sprayed simultaneously through a common orifice. Cross-linking via formation of thioether or disulfide bonds is initiated upon mixing, providing rapid gelation. The hydrogel components can be derivatized with RGD peptides or analogs thereof to promote retention in/on a body compartment such as the skin, surface of the eye, or a mucosa such as the vaginal mucosa. The cross-links are reversed using a reducing solution enabling easy removal of the hydrogel by dissolution. Processes for preparation of the cross-linker, RGD derivatized PEG and RGD-linked agents are also disclosed.Type: GrantFiled: April 23, 2008Date of Patent: December 15, 2015Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Stanley Stein, Anupa R. Menjoge, Simi Gunaseelan, Siva Naga Sree Priay Anumolu, Raghavandra Navath
-
Publication number: 20150283077Abstract: Formulations and methods for their preparation including a hydrogel including a crosslinked matrix comprising a polymer, and a one or more liposomes containing a therapeutic agent.Type: ApplicationFiled: March 12, 2015Publication date: October 8, 2015Inventors: Patrick J. Sinko, Stanley Stein, Anita Lalloo
-
Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases
Patent number: 9125835Abstract: Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.Type: GrantFiled: November 14, 2011Date of Patent: September 8, 2015Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Jieming Gao, Manjeet Deshmukh, Xiaoping Zhang, Matthew S. Palombo, Sherif Ibrahim -
Publication number: 20150202322Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: January 8, 2015Publication date: July 23, 2015Inventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Publication number: 20140335189Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Patent number: 8791234Abstract: Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed.Type: GrantFiled: October 14, 2011Date of Patent: July 29, 2014Assignee: Rutgers, The State University of New JerseyInventors: Patrick J. Sinko, Xiaoping Zhang, Zoltan Szekely
-
Publication number: 20140086975Abstract: Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.Type: ApplicationFiled: October 21, 2010Publication date: March 27, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Patrick J. Sinko, Manjeet Deshmukh, SivaNaga S. Anumolu, Anupa Menjoge, Marion Gordon
-
Publication number: 20140010862Abstract: A multifunctional polyethylene glycol-based hydrogel that includes a multi-arm polyethylene glycol cross-linking unit covalently bound to at least four multi-arm polyethylene glycol nanocarrier units, wherein each nanocarrier unit includes an agent coupled to the nanocarrier unit and each agent is selected from pH-lowering agents, bioadhesion agents, microbicidal-spermicidal agents, and agents that inhibit free and cell-associated HIV binding, provided that each nanocarrier unit comprises a different agent.Type: ApplicationFiled: November 15, 2011Publication date: January 9, 2014Applicant: Rutgers, The State University of New JerseyInventors: Patrick J. Sinko, Michael L. Chikindas, Stanley Stein, Yashveer Singh, Sujata S. Rajan, Dayuan Gao, Katia Noll